about
The membrane-anchored serine protease, TMPRSS2, activates PAR-2 in prostate cancer cellsNew insights into the mechanisms of green tea catechins in the chemoprevention of prostate cancerSSeCKS/Gravin/AKAP12 inhibits cancer cell invasiveness and chemotaxis by suppressing a protein kinase C- Raf/MEK/ERK pathway.The Regulation of Matrix Metalloproteinase Expression and the Role of Discoidin Domain Receptor 1/2 Signalling in Zoledronate-treated PC3 Cells.Desiccating stress decreases apical corneal epithelial cell size--modulation by the metalloproteinase inhibitor doxycycline.Cleavage of functional IL-2 receptor alpha chain (CD25) from murine corneal and conjunctival epithelia by MMP-9.Matrix metalloproteinases contribute distinct roles in neuroendocrine prostate carcinogenesis, metastasis, and angiogenesis progressionMatrix metalloproteinase biology applied to vitreoretinal disorders.Managing Sjögren's Syndrome and non-Sjögren Syndrome dry eye with anti-inflammatory therapy.Doxycycline induces caspase-dependent apoptosis in human pancreatic cancer cells.Cytotoxic effects of tetracycline analogues (doxycycline, minocycline and COL-3) in acute myeloid leukemia HL-60 cellsEndogenous matrix metalloproteinases 2 and 9 regulate activation of CD4+ and CD8+ T cells.Finasteride inhibits human prostate cancer cell invasion through MMP2 and MMP9 downregulation.Models of metastatic prostate cancer: a transgenic perspective.Association between MMP-2 expression and prostate cancer: A meta-analysisCigarette smoke modulates PC3 prostate cancer cell migration by altering adhesion molecules and the extracellular matrix.Molecular mechanism about lymphogenous metastasis of hepatocarcinoma cells in mice.Interleukin-17 promotes formation and growth of prostate adenocarcinoma in mouse models.Biotic acts of antibioticsIn silico profiling for secondary metabolites from Lepidium meyenii (maca) by the pharmacophore and ligand-shape-based joint approach.MMP16 is a marker of poor prognosis in gastric cancer promoting proliferation and invasion.A novel antisense inhibitor of MMP-9 attenuates angiogenesis, human prostate cancer cell invasion and tumorigenicity.Pharmacodynamic considerations in the use of matrix metalloproteinase inhibitors in cancer treatment.Protein kinase D1 inhibits cell proliferation through matrix metalloproteinase-2 and matrix metalloproteinase-9 secretion in prostate cancer.αvβ6 integrin is required for TGFβ1-mediated matrix metalloproteinase2 expression.Grape seed extract suppresses MDA-MB231 breast cancer cell migration and invasion.Potent anti-cancer effects of citrus peel flavonoids in human prostate xenograft tumors.Role of proprotein convertases in prostate cancer progression.Bradykinin enhances cell migration in human prostate cancer cells through B2 receptor/PKCδ/c-Src dependent signaling pathway.Prevalent expression of the immunostimulatory MHC class I chain-related molecule is counteracted by shedding in prostate cancerAction mechanism and signal pathways of Psidium guajava L. aqueous extract in killing prostate cancer LNCaP cells.Novel gene C17orf37 in 17q12 amplicon promotes migration and invasion of prostate cancer cells.CXCR6 is expressed in human prostate cancer in vivo and is involved in the in vitro invasion of PC3 and LNCap cells.The involvement of HAb18G/CD147 in regulation of store-operated calcium entry and metastasis of human hepatoma cells.A nonantibiotic chemically modified tetracycline (CMT-3) inhibits intimal thickeningFrom prostate to bone: key players in prostate cancer bone metastasis.Finasteride treatment alters MMP-2 and -9 gene expression and activity in the rat ventral prostate.Inhibition of cell proliferation, invasion, tumor growth and metastasis by an oral non-antimicrobial tetracycline analog (COL-3) in a metastatic prostate cancer model.Low plasma levels of matrix metalloproteinase 9 permit increased tumor angiogenesis.Effects of matrix metalloproteinase inhibitor on LPS-induced goblet cell metaplasia.
P2860
Q24534541-25BF2494-FA5E-47A6-9C1C-88DDC3C5603DQ24619151-ECA00B36-FD7A-4392-AD8E-BA6081A03065Q30433235-3C5D5A0F-0618-4EBE-95AB-D175ECD3C0C6Q30664167-ED09D53A-086F-4553-9B4A-9D085A7B0AF9Q33362899-C2D9B697-4D03-4F71-B4AC-26F5269003E2Q33514140-18E5CDE1-0FF1-4D6E-8BD8-ACCE54139618Q33732496-4D697215-564C-4EA9-9FE5-2228A15AA764Q33933063-12066499-F9FF-489B-8D6D-A3262656BDACQ34028408-63694DB2-995D-4947-86A3-885CF203AB59Q34585287-76686D28-6C93-4865-AFB8-74E8A74BB613Q34703798-7FFC5885-4390-43A5-A140-45FFC4A38023Q34985628-99EB177B-D9AB-488C-8839-01AF7CB828DAQ35081036-EB09090E-388D-422B-8CA6-A9BCBF7B16C9Q35217386-D37451A6-59CD-4DB2-9869-CE168BFFBD63Q35928166-11F6B3EC-0462-48E3-BFFF-B310DE612794Q36224712-F5806F6E-BB9E-40EC-B31D-BA74F453CA56Q36397228-C8FB8A4E-4A5C-44C0-8785-CAF013A1EA3DQ36879626-31BA3CCE-1E48-4A00-A87B-4A92528423BCQ37101851-70F65A52-1999-407B-A21E-95431FF5C938Q37286158-11400133-09C9-4155-BF75-D07D7A4AA1DEQ37588381-693154E3-6E45-455F-A674-AC13B0D7BD80Q38348323-A1FA45F1-EF6C-4668-B2ED-554DDF48C754Q38725320-78CDC121-4CFB-4767-9FFB-D6ABA9A485C8Q38768395-A5C21734-BE19-4EBA-B6D6-D6739F4899CFQ38923285-2B59AF72-F5A8-4091-B392-39D9C38D48AEQ39141324-CD6FDD3F-2C5F-43DA-91C6-078696B56597Q39152132-E9CEEC47-4E25-4EAB-9585-9DF014A6289DQ39229279-0FACF158-3702-4128-9043-018ED20CD616Q39338856-B47142C7-93F4-43F7-AF2F-7C8B54E6D1B9Q39676621-31CECF65-EBD7-4995-8E90-9C7047651CCAQ39748389-07371226-8C38-4292-BA0C-EF1D5DAC8C0EQ39841601-B692DA52-09D2-4A7A-AE5F-CBBC6CAFC6F3Q39985978-EB037607-7ADB-40D5-82C6-E8C0C950F7C6Q40776133-E30FBB4B-4B6D-489A-A4D0-21FE9A25B327Q41810809-D273DC6B-8C22-4FBF-A0F4-5BB676601DC1Q41904630-5B8D5AF0-FD25-41DF-9076-6EC28D265FF8Q44124064-F560AE11-DB4F-4C6A-B48A-5C4248093428Q45714438-012A1D15-7D43-4F78-BD98-54BBAAD00615Q45973048-48CD1C55-0F83-4A9E-9204-CD66F71D7D3AQ47952289-20ECC89E-ED75-42B7-B38D-7FA01C372F17
P2860
description
1999 nî lūn-bûn
@nan
1999 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի հունիսին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
name
MMP inhibition in prostate cancer.
@ast
MMP inhibition in prostate cancer.
@en
type
label
MMP inhibition in prostate cancer.
@ast
MMP inhibition in prostate cancer.
@en
prefLabel
MMP inhibition in prostate cancer.
@ast
MMP inhibition in prostate cancer.
@en
P2860
P1476
MMP inhibition in prostate cancer.
@en
P2093
Lokeshwar BL
P2860
P304
P356
10.1111/J.1749-6632.1999.TB07690.X
P407
P577
1999-06-01T00:00:00Z